Australia's most trusted
source of pharma news
Monday, 14 April 2025
Posted 11 April 2025 AM
Opthea's woes continue, with the Melbourne-based biotech announcing it is reducing its workforce by two-thirds in order to save cash.
The move comes after calamitous results from its Phase 3 COAST trial of VEGF-C and VEGF-D inhibitor sozinibercept, or OPT-302, in combination with Bayer's Eylea failed to meet its primary endpoint.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.